IE
MPLT

Israel Englander’s MapLight Therapeutics MPLT Stock Holding History

Israel Englander’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Buy
+128,841
New +$3.71M ﹤0.01% 3061
2026
Q1 		– Sell
-13,945
Closed -$245K – 6591
2025
Q4 		$245K Buy
+13,945
New +$234K ﹤0.01% 5369

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's MPLT Position: Q2 2026 in Review

Israel Englander opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 128,841 shares worth $4.62M. The stake represents ﹤0.01% of the portfolio and ranks #3061 among its holdings. This is a return to the name: Israel Englander previously reported a position in MPLT as recently as Q4 2025.

Israel Englander first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Israel Englander held 128,841 shares of MapLight Therapeutics worth $4.62M as of Q2 2026.
  • MapLight Therapeutics was a new Israel Englander position in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3061 holding.
  • Israel Englander first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.